The lymphoma and myeloma expert indicated that one of the key ways to address these disparities in lymphoma and myeloma is to improve minority and rural accrual in clinical trials.
The hematologist and medical oncologist discussed the approval of daratumumab and hyaluronidase-fihj for use in adult patients with newly diagnosed or relapsed/refractory multiple myeloma.
The FDA approved the use of daratumumab and hyaluronidase-fihj (Darzalex Faspro) in adult patients with newly diagnosed or relapsed/refractory multiple myeloma.
The International Lymphoma Radiation Oncology Group laid out a set of emergency recommendations for alternative radiation treatment schemes for treating patients with hematologic malignancies during the COVID-19 pandemic.
Karyopharm Therapeutics announced plans to commence a global randomized clinical trial for low dose oral selinexor in hospitalized patients with severe COVID-19.
A case study of a patient in Wuhan, China demonstrated that tocilizumab may be an effective treatment for very ill patients with COVID-19 who also have multiple myeloma and other blood cancers.
Researchers indicated that these results show the feasibility of this regimen and support the development of additional studies of melflufen in multiple myeloma, both in combination with dexamethasone as well as in triplet regimens.
A study analyzed a test for specific gene patterns that could indicate that a patient will not respond to standard treatment for newly diagnosed multiple myeloma.
The researchers indicated that the results could provide additional guidance for the decision-making process when clinicians are deciding on the most appropriate regimen for relapsed and/or refractory multiple myeloma.
ONCOLOGY recently sat down with Kenneth C. Anderson, MD, to discuss the current trends in multiple myeloma treatment, and the explosion of novel therapies that are paving the way to better and more durable outcomes and allowing patients to live longer and more meaningful lives.